摘要
晚期非小细胞肺癌提倡以化疗为主综合治疗,可以延长生存期,提高生存率。但目前化疗取得的疗效虽然较既往有提高,但提高生存期有限,且在药效经济学方面存在争议,缓解症状的作用也有限,联合靶向治疗的疗效也在观望中。临床肿瘤学工作者应正确认识,以循证医学为指导,开展规范化化疗,同时也注重个体化化疗,并期待晚期非小细胞肺癌化疗的新突破。
The multidisciplinary treatment plays an important role in advanced non- small cell lung cancer and chenlotherapy is the main treatment. The response rate of chenaotherapy in advanced non - small cell lung cancer is not satisfied and the improvement of survival time and quality of life （QOL） is limited. Targeted therapy in advanced non - small cell lung cancer is just a beginning. Survival time and quality of life are the main role in the treatment of advanced non - small cell lung cancer. Clinical oncologists should deliver chemotherapy bared on EBM and standardization for patients with advanced non- small cell lung cancer, pay attention to individualization, and hope new approach in this area.
出处
《医学与哲学（B）》
2006年第3期24-27,共4页
Medicine & Philosophy(B)
关键词
晚期非小细胞肺癌
化学治疗
疗效
循证医学
advanced non- small cell lung cancer, chemotherapy, curative effect, evidence-based medicine
